OrbiMed’s Exelixis EXEL Stock Holding History

OrbiMed’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-150,000	Closed	-$3.32M	–	150
2018 Q1	$3.32M	Buy	+150,000	New	+$4.15M	0.04%	126

Other funds holding EXEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

OrbiMed's EXEL Position: Q4 2020 in Review

OrbiMed sold out of Exelixis (EXEL) in Q4 2020, closing a stake of 2,404,100 shares — an estimated $58.8M sold.

OrbiMed first reported a position in EXEL in Q3 2013 and held it in 14 quarters. The position peaked at $83.6M in Q2 2019. 351 funds tracked by Wall St. Rank hold EXEL as of Q4 2020.

OrbiMed reported no remaining Exelixis position as of Q4 2020 after selling out during the quarter.
OrbiMed sold 2,404,100 Exelixis shares in Q4 2020, an estimated $58.8M.
OrbiMed first reported a position in Exelixis in Q3 2013 and held it in 14 quarters.
OrbiMed's Exelixis position peaked at $83.6M in Q2 2019.
351 funds tracked by Wall St. Rank held Exelixis as of Q4 2020.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.